BioSpace News Archive

SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced an additional FDA clearance for iFuse Bedrock Granite®.

PolarityTE, Inc. announced that it signed a non-binding letter of intent with Michael Brauser for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash.

AB Science SA announces that masitinib has been granted orphan drug status by the Swiss Agency for Therapeutic Products for the treatment of patients with amyotrophic lateral sclerosis.

InnoCare Pharma announced the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant by the Department of Health, the Hong Kong Special Administrative Region, China.

RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission relating to a proposed offering of its ordinary shares in the form of American Depositary Shares.

SpringWorks Therapeutics, Inc. announced that the Company has completed the submission of a New Drug Application to the United States Food and Drug Administration for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.

PeptiDream Inc. announced a new multi-target collaboration and license Agreement with U.S.-based Merck & Co, Inc., Rahway, N.J., U.S.A., known as “MSD” outside the U.S. and Canada, through a subsidiary, focused on the discovery and development of novel peptide drug conjugates.

Novocure announced it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023.

AcelRx Pharmaceuticals, Inc. announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 748,744 shares of its common stock, pre-funded warrants exercisable for an aggregate of 2,632,898 shares of common stock and common warrants exercisable for an aggregate of 4,227,052 shares of common stock.

Adaptive Biotechnologies Corporation announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.